MX2021006943A - Anelosomas para suministrar modalidades terapéuticas secretadas. - Google Patents

Anelosomas para suministrar modalidades terapéuticas secretadas.

Info

Publication number
MX2021006943A
MX2021006943A MX2021006943A MX2021006943A MX2021006943A MX 2021006943 A MX2021006943 A MX 2021006943A MX 2021006943 A MX2021006943 A MX 2021006943A MX 2021006943 A MX2021006943 A MX 2021006943A MX 2021006943 A MX2021006943 A MX 2021006943A
Authority
MX
Mexico
Prior art keywords
anellosomes
therapeutic modalities
secreted therapeutic
delivering
delivering secreted
Prior art date
Application number
MX2021006943A
Other languages
English (en)
Spanish (es)
Inventor
Avak Kahvejian
Erica Gabrielle Weinstein
Simon Delagrave
Nathan Lawrence Yozwiak
Kevin James Lebo
Fernando Martin Diaz
Dhananjay Maniklal Nawandar
Ryan D Tedstone
Jared David Pitts
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of MX2021006943A publication Critical patent/MX2021006943A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2021006943A 2018-12-12 2019-12-12 Anelosomas para suministrar modalidades terapéuticas secretadas. MX2021006943A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778866P 2018-12-12 2018-12-12
US201862778869P 2018-12-12 2018-12-12
PCT/US2019/065919 WO2020123773A2 (en) 2018-12-12 2019-12-12 Anellosomes for delivering secreted therapeutic modalities

Publications (1)

Publication Number Publication Date
MX2021006943A true MX2021006943A (es) 2021-11-17

Family

ID=69160343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006943A MX2021006943A (es) 2018-12-12 2019-12-12 Anelosomas para suministrar modalidades terapéuticas secretadas.

Country Status (11)

Country Link
US (2) US20230048858A1 (cg-RX-API-DMAC10.html)
EP (1) EP3894568A2 (cg-RX-API-DMAC10.html)
JP (2) JP2022512395A (cg-RX-API-DMAC10.html)
KR (1) KR20210131309A (cg-RX-API-DMAC10.html)
CN (1) CN113631717A (cg-RX-API-DMAC10.html)
AU (1) AU2019396520A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021009379A2 (cg-RX-API-DMAC10.html)
CA (1) CA3119531A1 (cg-RX-API-DMAC10.html)
IL (1) IL283778A (cg-RX-API-DMAC10.html)
MX (1) MX2021006943A (cg-RX-API-DMAC10.html)
WO (1) WO2020123773A2 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11624061B2 (en) 2017-04-28 2023-04-11 Agrospheres, Inc. Compositions and methods for enzyme immobilization
BR112020005803A2 (pt) 2017-09-25 2020-12-01 Agrospheres, Inc. composições e métodos para produção e administração moduláveis de produtos biológicos
JP2022513459A (ja) * 2018-12-12 2022-02-08 フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド タンパク質代替治療モダリティを送達するためのアネロソーム
CA3121528A1 (en) 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
KR20230041686A (ko) * 2020-06-17 2023-03-24 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 아넬로바이러스를 확인 및 특징화하는 방법 및 이의 용도
US20240000914A1 (en) * 2020-10-29 2024-01-04 Flagship Pioneering Innovations V, Inc. Chicken anemia virus (cav)-based vectors
WO2022170195A1 (en) * 2021-02-08 2022-08-11 Flagship Pioneering Innovations V, Inc. Hybrid aav-anellovectors
EP4337235A4 (en) * 2021-05-12 2025-07-02 Flagship Pioneering Innovations V Inc ANELLOVECTORS AND METHODS OF USE
CN118284411A (zh) * 2021-10-12 2024-07-02 旗舰先锋创新V股份有限公司 新颖的指环载体组合物和方法
MX2024004492A (es) * 2021-10-12 2024-05-31 Flagship Pioneering Innovations V Inc Composiciones y metodos de anellovector novedosos.
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任(Vii)公司 用於將治療劑遞送至骨之組成物和方法
TW202529819A (zh) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 組織特異性指環載體(anellovector)遞送
CN117695410B (zh) * 2024-02-06 2024-05-03 中国人民解放军军事科学院军事医学研究院 CRISPR/Cas9纳米抗菌剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395472B1 (en) * 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
CN111206032B (zh) * 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
EP3359663A4 (en) * 2015-09-24 2019-08-14 The Trustees of The University of Pennsylvania COMPOSITION AND METHOD FOR THE TREATMENT OF A COMPLEMENT-MEDIATED DISEASE
CA3066750A1 (en) * 2017-06-13 2018-12-20 Flagship Pioneering Innovations V, Inc. Compositions comprising curons and uses thereof
KR20200067195A (ko) * 2017-10-18 2020-06-11 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항체 치료제

Also Published As

Publication number Publication date
EP3894568A2 (en) 2021-10-20
CN113631717A (zh) 2021-11-09
JP2022512395A (ja) 2022-02-03
WO2020123773A9 (en) 2020-08-27
CA3119531A1 (en) 2020-06-18
BR112021009379A2 (pt) 2021-08-17
WO2020123773A3 (en) 2020-07-23
US20260009050A1 (en) 2026-01-08
IL283778A (en) 2021-07-29
JP2024100936A (ja) 2024-07-26
WO2020123773A2 (en) 2020-06-18
AU2019396520A1 (en) 2021-05-27
US20230048858A1 (en) 2023-02-16
KR20210131309A (ko) 2021-11-02

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
BR112021024754A2 (pt) Vesículas extracelulares microbianas secretadas
PE20200617A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39
MX2018015252A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2019015018A (es) Composiciones que comprenden curones y usos de los mismos.
PE20201419A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
BR112021011124A2 (pt) Anelossomos e métodos de uso
BR112019004783A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
DK3740504T5 (da) CD70 kombinationsterapi
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
CL2021002331A1 (es) Formulaciones de anticuerpo anti-il-36r
MX2018003700A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
WO2020123773A3 (en) Anellosomes for delivering secreted therapeutic modalities
EP3860585A4 (en) Therapeutic compositions
EP3735463A4 (en) Cytotoxicity-inducing therapeutic agent
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
MX2021006941A (es) Anelosomas para suministrar modalidades terapéuticas intracelulares.
EP3864058A4 (en) PHOTOCURABLE COMPOSITION
UY35463A (es) Formulaciones de polipéptido fc-factor ix.
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
MX388186B (es) Granos de gluten reducido y composiciones de los mismos.